GENZOR, Samuel, Pavol POBEHA, Martin SIMEK, Petr JAKUBEC, Jan MIZERA, Martin VYKOPAL, Milan SOVA, Jakub VANEK and Jan PRASKO. Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19. LIFE-BASEL. BASEL: MDPI, 2023, vol. 13, No 4, p. 1-11. ISSN 2075-1729. Available from: https://dx.doi.org/10.3390/life13041054.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19
Authors GENZOR, Samuel (203 Czech Republic, guarantor), Pavol POBEHA (705 Slovenia), Martin SIMEK (203 Czech Republic), Petr JAKUBEC (203 Czech Republic), Jan MIZERA (203 Czech Republic), Martin VYKOPAL (203 Czech Republic), Milan SOVA (203 Czech Republic, belonging to the institution), Jakub VANEK (203 Czech Republic) and Jan PRASKO (203 Czech Republic).
Edition LIFE-BASEL, BASEL, MDPI, 2023, 2075-1729.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.200 in 2022
RIV identification code RIV/00216224:14110/23:00131203
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/life13041054
UT WoS 000979236800001
Keywords in English ECMO; COVID-19; long-term outcome
Tags 14110215, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/7/2023 10:19.
Abstract
Introduction: Severe respiratory failure is one of the most serious complications of coronavirus disease 2019 (COVID-19). In a small proportion of patients, mechanical ventilation fails to provide adequate oxygenation and extracorporeal membrane oxygenation (ECMO) is needed. The surviving individuals need long-term follow-up as it is not clear what their prognosis is. Aim: To provide a complex clinical picture of patients during follow-up exceeding one year after the ECMO therapy due to severe COVID-19. Methods: All subjects involved in the study required ECMO in the acute stage of COVID-19. The survivors were followed-up for over one year at a specialized respiratory medical center. Results: Of the 41 patients indicated for ECMO, 17 patients (64.7% males) survived. The average age of survivors was 47.8 years, and the average BMI was 34.7 kg center dot m(-2). The duration of ECMO support was 9.4 days. A mild decrease in vital capacity (VC) and transfer factor (DLCO) was observed on the initial follow-up visit (82.1% and 60%, respectively). VC improved by 6.2% and by an additional 7.5% after 6 months and 1 year, respectively. DLCO improved by 21.1% after 6 months and remained stable after 1 year. Post-intensive care consequences included psychological problems and neurological impairment in 29% of patients; 64.7% of the survivors got vaccinated against SARS-CoV-2 within 12 months of hospitalization and 17.6% experienced reinfection with a mild course. Conclusion: The COVID-19 pandemic has significantly increased the need for ECMO. Patients' quality of life after ECMO is temporarily significantly reduced but most patients do not experience permanent disability.
PrintDisplayed: 23/7/2024 20:25